CCI
MDGL icon

Columbus Circle Investors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Columbus Circle Investors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-54,809
Closed -$6.87M – 174
2019
Q1 		$6.87M Sell
54,809
-1,086
-2% -$135K 0.17% 119
2018
Q4 		$6.3M Buy
55,895
+29,587
+112% +$4.58M 0.18% 112
2018
Q3 		$5.63M Buy
+26,308
New +$6.6M 0.11% 146

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Columbus Circle Investors's MDGL Position: Q2 2019 in Review

Columbus Circle Investors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 54,809 shares — an estimated $6.87M sold.

Columbus Circle Investors first reported a position in MDGL in Q3 2018 and held it in 3 quarters. The position peaked at $6.87M in Q1 2019. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Columbus Circle Investors reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Columbus Circle Investors sold 54,809 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $6.87M.
  • Columbus Circle Investors first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Columbus Circle Investors's Madrigal Pharmaceuticals position peaked at $6.87M in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Columbus Circle Investors's 13F filing for Q2 2019, filed 2 Aug 2019.